Clinical Updates & Insights

Share

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed

Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
185 Clinical Updates found
A Q&A with MSK’s Dr. Jonathan Coleman
Kidney-Sparing Treatment Options for Upper Tract Urothelial Carcinoma With and Without Lynch Syndrome

MSK’s comprehensive program for patients with upper tract urothelial carcinoma (UTUC) offers kidney-sparing treatment options whenever possible.
MSK AACR 2024 Research Roundup: Highlights of Exciting Advances in Foundational and Translational Research
MSK AACR 2024 Research Roundup: Highlights of Exciting Advances in Foundational and Translational Research

Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest foundational and translational cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5 to 10 in San Diego.
Adoptive Cell Therapy Improves Outcomes for Select Patients With Advanced Synovial Sarcoma
Adoptive Cell Therapy Improves Outcomes for Select Patients With Advanced Synovial Sarcoma

The adoptive cell therapy afamitresgene autoleucel (afami-cel) demonstrated a favorable response and duration of response in select patients with metastatic synovial sarcoma, according to results from an international phase 2 clinical trial published recently in The Lancet. 
Biological Insights Fuel Novel Treatments for Rare Head and Neck Cancers
Biological Insights Fuel Novel Treatments for Rare Head and Neck Cancers (Part 1: Rare Salivary Cancers)

This three-part series summarizes MSK’s recent advances in clinical research and novel treatment approaches for rare head and neck cancers.
Biological Insights Fuel Novel Treatments for Rare Head and Neck Cancers
Biological Insights Fuel Novel Treatments for Rare Head and Neck Cancers (Part 2: Rare Thyroid Cancers)

This article is Part 2 of our three-part series on MSK-led advances for improving outcomes for patients with rare head and neck cancers.
Biological Insights Fuel Novel Treatments for Rare Non-Melanoma Skin and Oral Cavity Cancers
Biological Insights Fuel Novel Treatments for Rare Non-Melanoma Skin and Oral Cavity Cancers (Part 3)

This article is Part 3 of our three-part series summarizing how MSK’s biological insights and expertise fuel innovative treatment approaches for patients with rare head and neck cancers.
Salvage Surgery After Initial Nonoperative Treatment Increased Survival in Select Patients with Lung Cancer
Salvage Surgery After Initial Nonoperative Treatment Increased Survival in Select Patients with Lung Cancer

Lung resection after initial nonoperative treatment for non-small cell lung cancer (NSCLC) was safe and led to significantly improved survival in select patients previously treated with nonoperative therapies, according to a study by Memorial Sloan Kettering Cancer Center (MSK) investigators.
10 Trials and Growing: A Progress Update on the Thoracic Surgical Oncology Group Clinical Trials
10 Trials and Growing: A Progress Update on the Thoracic Surgical Oncology Group Clinical Trials

The Thoracic Surgery Oncology Group (TSOG) is a joint initiative between the American Association for Thoracic Surgery and the Fiona & Stanley Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center (MSK).
urologic surgeon Jose Flores, MD, MHA
ED Drugs Do Not Increase Risk of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

A new study by investigators at Memorial Sloan Kettering Cancer Center (MSK) found no evidence of an increased risk of biochemical recurrence with any PDE5 inhibitor use or duration in the first year following radical prostatectomy.
Rectal Cancer Response to Total Neoadjuvant Therapy Predicts Organ Preservation and Survival Outcomes
Rectal Cancer Response to Total Neoadjuvant Therapy Predicts Organ Preservation and Survival Outcomes

The Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial demonstrated that the watch-and-wait strategy is safe for patients with stage 2 and stage 3 rectal cancers that achieve a clinical complete response (CCR) or near-complete clinical response (NCR) to total neoadjuvant therapy (TNT).